文献速递临床微生物分子诊断

BioFire FilmArray BCID2 在临床血培养处理中的应用价值

Usefulness of BioFire FilmArray BCID2 for Blood Culture Processing in Clinical Practice.
PubMed 文献 · J Clin Microbiol · 2021-07-19

该研究评估了 BioFire FilmArray BCID2 检测对 180 份阳性血培养的物种鉴定性能。BCID2 结果与标准方法在 159/180(88.3%)份血培养中一致,单菌培养中革兰阳性菌和革兰阴性菌的一致率分别为 68/74(91.9%)和 71/74(96.0%)。不一致主要与多菌感染及耐药基因预测局限性有关,提示 BCID2 需与表型药敏试验结合使用。

要点

  • BCID2 与标准方法总体一致率为 88.3%(159/180),单菌革兰阳性菌和阴性菌一致率分别为 91.9% 和 96.0%。
  • 多菌血培养中不一致结果占 38.7%(12/31),需警惕混合感染时的判读。
  • BCID2 检出 12 份 blaCTX-M 阳性标本,但 4 株因其他耐药机制未预测出三代头孢耐药。

核心结论

  • BCID2 是快速处理血培养和物种鉴定的可靠工具,但与标准方法总体一致率为 88.3%(159/180)。
  • 尽管包含常见 ESBL 或碳青霉烯酶编码标记,革兰阴性菌 β-内酰胺耐药的多因素性质要求将 BCID2 与(快速)表型药敏试验联合使用。

研究设计与样本

  • 研究评估了 BCID2 检测对 180 份阳性血培养进行物种鉴定的临床性能,以标准方法为参照。

主要发现

  • BCID2 结果与标准方法在 159/180(88.3%)份血培养中一致。
  • 单菌培养中,革兰阳性菌和革兰阴性菌与标准方法一致率分别为 68/74(91.9%)和 71/74(96.0%)。
  • 不一致原因包括 BCID2 检出额外病原体(n=4)、物种鉴定差异(n=4)或未检出面板内病原体(n=1)。
  • 12/31(38.7%)的不一致结果出现在多菌血培养标本中。
  • BCID2 在 12 份血培养中检出携带 blaCTX-M 的物种,但未能预测 4 株具有独立头孢菌素耐药机制菌株的三代头孢耐药性;2 株 blaVIM-2 或 blaOxa-48-like 相关的碳青霉烯耐药被正确预测。

临床怎么用

  • BCID2 可用于阳性血培养的快速物种鉴定,但耐药预测需结合表型药敏试验。
  • 对多菌血培养结果及 BCID2 未预测出的耐药表型应保持警惕。

局限性

  • 不一致结果部分与多菌血培养标本有关(12/31;38.7%)。
  • BCID2 未能预测具有独立耐药机制菌株的三代头孢耐药性(4 株)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rapid pathogen characterization from positive blood cultures (BC) can improve management of patients with bloodstream infections (BSI). The FilmArray blood culture identification (BCID) assay is a molecular test approved for direct identification of BSI causing pathogens from positive BC. A recently updated version of the panel (BCID2) comprises improved species identification characteristics and allows for the detection of one expanded-spectrum β-lactamase (ESBL)- and several carbapenemase-encoding genes. Here, the clinical performance of the BCID2 assay for species identification in 180 positive BCs was evaluated. BCID2 results were concordant with the standard of care (SOC) in 159/180 (88.3%) BCs; 68/74 (91.9%) and 71/74 (96.0%) of all samples growing monobacterial, Gram-positive or Gram-negative pathogens, respectively, were identified, in agreement with SOC results. Nonconcordance was related to the detection of additional pathogens by the BCID2 assay (n = 4), discrepant species identification (n = 4), or failure of BCID2 to detect on-panel pathogens (n = 1). A number (12/31; 38.7%) of discordant results became evident in polymicrobial BC specimens. BCID2 identified the presence of blaCTX-M-carrying species in 12 BC specimens but failed to predict third-generation cephalosporin resistance in four isolates exhibiting independent cephalosporin resistance mechanisms. Carbapenem resistance related to the presence of blaVIM-2 or blaOxa-48-like was correctly predicted in two isolates. In conclusion, the BCID2 assay is a reliable tool for rapid BC processing and species identification. Despite inclusion of common ESBL- or carbapenemase-encoding markers, the multifactorial nature of β-lactam resistance in Gram-negative organisms warrants combination of BCID2 with (rapid) phenotypic susceptibility assays.

来源:J Clin Microbiol,查看原文。版权归原作者所有。

引用

  1. Berinson B, Both A, Berneking L, et al. Usefulness of BioFire FilmArray BCID2 for Blood Culture Processing in Clinical Practice. J Clin Microbiol. 2021. PMID: 33980648. doi:10.1128/JCM.00543-21

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。